Tag: checkpoint inhibitors for CRC

Home / checkpoint inhibitors for CRC

Categories

Nivolumab with ipilimumab is approved by the USFDA for unresectable or metastatic MSI-H or dMMR colorectal cancer

On April 8, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) and ipilimumab (Yervoy, Bristol Myers Squibb Company) for adults and children 12 years and ...
checkpoint-inhibitors-for-crc

Scan the code